Table 2.
Assay test results of artemether–lumefantrine samples (N = 74) collected from low and high malaria transmission settings in Uganda, June-December 2021
| Brand name | Artemether label claim (mg) | Number of samples tested n (%) | Number of samples with artemether content outside pharmacopeiala range (90–110%) n (%) |
Number of samples with lumefantrine content outside pharmacopeiala range (90–110%) n (%) |
|---|---|---|---|---|
| LONART | 20/120 | 20 (27%) | 4 (5.4%) | 2 (2.7%) |
| 40/240 | 1 (1.4%) | 0 | 0 | |
| 80/480 | 3 (4.1%) | 0 | 0 | |
| LONART-DS | 80/480 | 1 (1.4%) | 0 | 0 |
| ARTEFAN | 20/120 | 12 (16.2%) | 0 | 0 |
| 40/240 | 1 (1.4%) | 0 | 0 | |
| 60/360 | 1(1.4%) | 0 | 0 | |
| 80/480c | 1(1.4%) | 1(1.4%) | 1 (1.4%) | |
| LUMARTEM | 20/120 | 2 (2.7%) | 0 | 0 |
| 80/480 | 1 (1.4%) | 0 | 0 | |
| CO-METHER | 20/120 | 5 (6.8%) | 1 (1.4%) | 0 |
| KOMEFAN-140 | 20/120 | 1 (1.4%) | 1(1.4%) | 0 |
| COMBIART | 20/120 | 5 (6.8%) | 0 | 0 |
| LUMERAX | 20/120 | 1 (1.4%) | 1 (1.4%) | 0 |
| LARIACT | 20/120 | 3 (4.1%) | 0 | 1 (1.4%) |
| Cach-ARTb | 20/120 | 2 (2.7%) | 2 (2.7%) | 1 (1.4%) |
| LUMAREN | 20/120 | 2 (2.7%) | 0 | 0 |
| COARTEM | 20/120 | 1 (1.4%) | 0 | 0 |
| KOMEFAN | 20/120 | 1 (1.4%) | 0 | 0 |
| LUMITER | 20/120 | 6 (8.1%) | 1 (1.4%) | 0 |
| Not Indicated | 20/120 | 4 (5.4%) | 0 | 0 |
| Total number | 74 (100%) | 11 (14.9%) | 5(6.8%) | |
aWHO and US Pharmacopeia (90–110%)
bOne batch (CHRT21001E) of this brand failed both artemether and lumefantrine assay test
cThe sample was not registered for use in the country by the National drug regulator and was classified as substandard regardless of assay results as per the WHO guidelines